Postnatal mammalian cardiomyocytes undergo a major transition from hyperplasia (increases in cell numbers) to hypertrophy (expansion in cell size). This process is accompanied by rapid mitochondrial biogenesis and metabolic switches to meet the demand of increased cardiac output.
dilated cardiomyopathy (2, 12) . Analyses of 5,000 knockout mouse lines by the International Mouse Phenotype Consortium revealed that knockout of the mouse homolog of COQ2, COQ4, COQ6, COQ8B, PDSS1 or PDSS2 in mice are homozygous-lethal (13) , highlighting the essential role of CoQ synthesis in development. A mouse model Coq9 R239X harboring a premature stop codon found in a human patient presents widespread tissue deficiency of CoQ and develops signs of cardiac fibrosis (14) . So far, mutations in the COQ10A gene have never been reported in humans. Here we show that rodent Coq10a (a homolog of human COQ10A) is predominantly expresses in the heart muscle mitochondria. The mRNA level of Coq10a is positively regulated by thyroid hormone signaling in postnatal mouse heart and isolated cardiomyocytes. To understand the physiological function of Coq10a, we generated Coq10a knockout mice using the CRISPR/Cas9-based genome editing technique. Coq10a mutant mice showed cardiac hypertrophic phenotype without any features of pathological hypertrophy such as fetal gene expression, cardiac dysfunction and fibrosis. Furthermore, Coq10a knockout hearts have intact mitochondrial respiration and contain higher levels of CoQ, indicating that although mouse Coq10a can rescue the lethal phenotype in yeast coq10 mutants, it has unique functions in the mammalian heart that are distinct from yeast Coq10p.
Results

Coq10a is a novel mitochondrial protein predominantly expressed in postnatal striated muscles
We analyzed a rat RNA-seq transcriptomic BodyMap across 11 organs (15) and revealed that Coq10a is predominantly expressed in the skeletal muscle and heart at 21 weeks of age ( Figure   1A ) while its paralog Coq10b is highly expressed in the adrenal gland but present in most other organs at a low level ( Figure S1A ). In addition, a recent detailed analysis of gene expression across mouse organ development showed that cardiac expression of Coq10a begins around E15.5, rapidly increases postnatally and keeps increasing by postnatal day 63 (P63) ( Figure 1B) ; Coq10b expression follows a similar temporal pattern in the heart ( Figure S1B) (16) . In the adult mouse heart, Coq10a expression is 4-5 folds higher than Coq10b (Figure 1B and S1B) . Consistently, we found that Coq10a protein levels increase in the mouse heart during postnatal development ( Figure 1C ).
Because yeast Coq10p protein localizes to the inner mitochondrial membrane (4, 6) , we investigated whether mouse Coq10a is also a mitochondrial protein. Subcellular fractionation of the adult mouse ventricular tissue indeed showed that Coq10a is highly enriched in the mitochondrial fraction rather than the cytosolic fraction ( Figure 1C ). Altogether, these results support Coq10a as a striated-muscle enriched mitochondrial protein.
Thyroid hormone signaling activates Coq10a gene expression
Because the temporal dynamics of Coq10a expression matches that of circulating thyroid hormones (17) and expression of downstream target genes such as Myh6 (18), we hypothesized that Coq10a gene expression is controlled by thyroid hormone signaling in the heart. Thyroid hormone receptors are transcription factors that bind DNA directly and regulate the expression of target genes.
We first tested whether increase of thyroid hormones is sufficient to activate Coq10a expression in primary mouse neonatal cardiomyocytes. Supplementation of culture media with triiodothyronine (T3) enhanced the gene expression of Coq10a by ~2.5 folds in primary cardiomyocytes ( Figure 2A ). Thus, these results suggest that activation of thyroid hormone signaling induces Coq10a gene expression.
To test if thyroid hormone signaling is necessary for Coq10a expression in the heart, we analyzed its transcript levels in mice that express a dominant negative form of thyroid hormone receptor alpha (Thra DN ) to suppress thyroid hormone signaling specifically in cardiomyocytes (Myh6-Cre;Thra DN ), recently generated by our laboratory (19) . RNA-seq analyses of Myh6-Cre;Thra DN hearts at P14 demonstrated that the gene expression of Coq10a was reduced to one-third compared to control hearts ( Figure 2B ). Consistently, Coq10a protein was also reduced in Myh6-Cre;Thra DN hearts at P14, compared to the littermate control. Furthermore, our chromatin immunoprecipitation-sequencing (ChIP-seq) analysis revealed that thyroid hormone receptor alpha binds to the first intron of Coq10a ( Figure 2D ), thus both RNA-seq and ChIP-seq results provide strong supports for Coq10a as a direct target gene of thyroid hormone receptors. In sum, our findings demonstrate that thyroid hormone signaling activation is important for the cardiac gene expression of Coq10a.
Mice lacking Coq10a develops cardiac hypertrophy at postnatal day 14
In fission yeast Coq10p, Phe39-Lys45 have been mapped as key CoQ-binding residues (7) . In this sequence, Phe39 and Pro41 are two highly conserved amino acids from bacteria to human ( Figure 3A ) and have been shown by site-directed mutagenesis to be essential for CoQ interaction (7) . To generate Coq10a knockout mice, we exploited the CRISPR/Cas9-based genome-editing technique and designed sgRNA targeting the upstream of the conserved ubiquinone-binding site ( Figure 3B ). Sequencing of one stable line of mutant mice at the F2 generation revealed an insertion of two nucleic acids at the targeted site, resulting in frameshift mutations, which produces a truncated Coq10a protein lacking the ubiquinone-binding site ( Figure  3B ). Coq10a protein expression was decreased in the Coq10a +/heterozygous heart and was undetectable in heart of adult Coq10a -/homozygous mutant mice ( Figure 3C ).
Coq10a -/mutant mice are born at Mendelian ratio with normal gross morphology and fertility. We first evaluated heart phenotypes at P14. Coq10a -/mutant mice had an increase of the ratio of heart weight-to-body weight by 22% despite normal body weight ( Figure 4A and 4B), indicating that depletion of Coq10a gene results in a cardiomegaly phenotype. This phenotype is further confirmed in seven F0 Coq10a homozygous mutant mice at P14 ( Figure S2 ). Although gene editing using the CRISPR/Cas9 system might cause off-target effects, the highly reproducible cardiomegaly phenotype in F2 and multiple F0 mutant animals suggest that the phenotype is likely a consequence of the specific loss of Coq10a.
To determine if the increased heart size is due to cardiomyocyte hypertrophy or hyperplasia, we first assessed the size of individual cardiomyocytes isolated from ventricle of P14 Coq10a -/mice. Cardiomyocyte size was significantly increased in Coq10a -/mice ( Figure 4C ). Next, to evaluate a possible contribution of hyperplasia to the cardiomegaly phenotype, we evaluated cardiomyocyte number, nucleation, proliferation and apoptosis in Coq10a -/and control littermate mice at P14. Analyses of mutant and control mice showed comparable total cardiomyocyte numbers in the ventricle ( Figure 4D ) and cardiomyocyte nucleation distribution ( Figure 4E ). Proliferating cardiomyocytes was assessed by immunostaining against cardiomyocyte nuclear marker pericentriolar material 1 (PCM1) and a proliferation marker Ki67. However, we observed no difference in proliferating cardiomyocytes between Coq10a -/mice and littermate controls ( Figure 4F ).
To assess the extent of cell apoptosis, terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end labeling (TUNEL) assays were performed on histological sections and no difference in the number of TUNEL-positive cardiomyocytes was observed between Coq10a -/and control mice ( Figure 4G ). Therefore, our investigation suggests that the cardiomegaly is primarily due to increase in cardiomyocyte size, which is indicative of cardiac hypertrophy.
To understand how deletion of Coq10a led to heart hypertrophy, we performed RNA-seq analyses of Coq10a -/and control hearts at P14. By gene ontology (GO) analysis, we found upregulated genes primarily in the categories of mitochondrion and metabolic process while downregulated genes mainly in the membrane, cell-cell junction and focal adhesion categories ( Figure 5A ). Moreover, gene-set enrichment analyses (GSEA) revealed citrate (TCA) cycle, Peroxisome Proliferator-Activated Receptor (PPAR) signaling pathway, fatty acid metabolism, and valine-leucine-isoleucine degradation pathway genes were significantly up-regulated ( Figure 5B ). In the genes down-regulated in Coq10a -/mutant heart, we found an enrichment of components involved in extracellular matrix receptor interaction, dilated cardiomyopathy, DNA replication and hypertrophic cardiomyopathy ( Figure 5B ). Consistent with the upregulation of mitochondrial and metabolic genes, we found that Ppargc1a (also known as Pgc1α), Pparg and Rxrg expression significantly increased in the mutant heart ( Figure 5C ). These genes encode transcription factors that function as master regulators of mitochondrial biogenesis and energy metabolism.
Among the genes whose expressions are significantly altered in the Coq10a -/mutant heart, we identified Growth/differentiation factor 15 (Gdf15), c-Myc (myc), Metallothionein 2 (Mt2) ( Figure 5D ) that have been previously shown to either induce cardiomyocyte hypertrophic growth or protect the heart against oxidative stress in hypertrophy (20) (21) (22) (23) . It was demonstrated that GDF15 proteins increased the rate protein synthesis by 47% and cardiomyocyte hypertrophic growth by 27% in vitro (20) . Mice with inducible expression of c-Myc in post-mitotic cardiomyocytes develop cardiac hypertrophy through enhanced free fatty acid utilization and oxidative metabolism (21) . Mt2 is highly up-regulated in pregnancy-induced cardiac hypertrophy and overexpression of Mt2 in mice has protective effects on cardiac oxidative stress through the antioxidant property of Metallothioneins (22, 23) .
We next examined our RNA-seq data for possible gene expression signature of pathological cardiac hypertrophy. Development of pathological hypertrophy is accompanied by up-regulation of fetal heart genes such as Acta1, Myh7, Nppa, Nppb and Atp2a2. The expression of these genes, however, is not significantly activated in our mutant mice ( Figure 5E ). In pathological hypertrophic heart, cardiac fibroblasts differentiate into myofibroblasts that produce type I collagen to progress cardiac fibrosis. The expression level of alpha-smooth muscle actin (α-SMA) (Acta2), which is known as a marker for differentiation of fibroblasts into myofibroblasts was not increased in our mutant mice. Consistently, no increase of type I collagen gene expression (Col1a1 and Col1a2) was observed in Coq10a -/heart ( Figure S3B ). Moreover, pathological hypertrophy is commonly accompanied by myocardial cell death. We did not observe any increased expression of executioner caspase genes (Casp3, 6 and 7) or apoptosis associated genes (Bax and Bcl2) in our mutant heart ( Figure S3A ), which is consistent with the TUNEL analysis ( Figure 4G ). In addition, the expression of Coq family genes including Coq10b was not altered in Coq10a mutant ( Figure S4 ), indicating that there was no compensational upregulation of other Coq family genes.
Adult Coq10a knockout mice maintain cardiac hypertrophy with preserved cardiac functions and mitochondrial respiration
Next we analyzed cardiac phenotypes of Coq10a knockout mice in adulthood. Compared to littermate wild type, the ratio of heart weight to body weight in adult Coq10a -/heart increased 25 % ( Figure 6A ), which is comparable with the extent of heart size change at P14. Consistent with comparable expression of collagen type I genes at P14, adult Coq10a -/mutant hearts did not display significant fibrosis ( Figure 6B ). Furthermore, echocardiography showed similar contractile functions between Coq10a knockout and control heart, suggesting preserved cardiac function in Coq10a -/mice ( Figure 6C ). Even in eight months old mutant mice, we did not observe any defects in cardiac function. In addition, blood pressure and heart rate measurements indicate that Coq10a -/heart functions normally in terms of systolic blood pressures and heart rate ( Figure 6D ). Taken together, our results suggest that knockout of Coq10a leads to transcriptional up-regulation of hypertrophy-inducing genes without any features of pathological hypertrophy or heart failure.
Yeast Coq10p has been hypothesized to be a CoQ binding protein which transports CoQ from the synthase complex to proper positions in the mitochondrial inner membrane (4) . Mutations of COQ10 in yeast cause decreased or normal level of coenzyme Q, with mitochondrial respiration defects (4). To investigate the role of Coq10a in mitochondrial biogenesis and function, we first isolated mitochondria from Coq10a -/mutant and control hearts. Intriguingly, the total amount of protein from purified mitochondria per ventricle significantly increased from 565 ± 52.9 mg in control hearts to 959 ± 58.4 mg in mutant hearts ( Figure 7A ). Next, we measured the oxygen consumption rate (OCR) in isolated mitochondria but found no significant difference between Coq10a -/and littermate control mice ( Figure 7B ). This result suggests that in contrast to yeast coq10 mutants, Coq10a -/mutant mice have intact mitochondrial respiration in the heart ( Figure 7B ). Furthermore, we analyzed the levels of CoQ 9 (the main coenzyme Q specie in mice) and CoQ 10 by high performance liquid chromatography (HPLC) and demonstrated 1.7-fold increase of CoQ 9 and 2.1-fold increase of CoQ 10 in Coq10a -/hearts, compared to control ( Figure 7C ). Consistently, we found that the ratio of mitochondria DNA to nuclear DNA were almost doubled in the Coq10a -/heart ( Figure 7D ), suggesting that deletion of Coq10a may result in an accumulation of functional mitochondria and coenzyme Q in the mouse heart. The increase of mitochondrial proteins and DNA could be explained by upregulation of Pgc1α gene expression in the Coq10a -/heart ( Figure 5C ). PGC1α is a master regulator of mitochondrial biogenesis and energy metabolism. Cardiac-specific overexpression of Pgc1α to a non-physiological high-level leads to pathological cardiac hypertrophy followed by uncontrolled mitochondrial biogenesis and loss of sarcomere structure (24, 25) . Although the expression of Pgc1α and its downstream genes are generally downregulated in pathological hypertrophy (26) , exercise-induced physiological hypertrophy shows moderate increases (approximately 50-80%) of Pgc1α expression (27) (28) (29) (30) (31) . Thus, the 67% increase of Pgc1α mRNA in the Coq10a -/heart ( Figure 5C ) would be consistent with the mutant heart and mitochondrial phenotypes. In sum, our findings suggest that depletion of Coq10a increases mitochondrial content with preserved mitochondrial respiration in the heart possibly through PGC1α pathway activation.
Discussion
In this report, we used a genetic approach to investigate the physiological function of the Based on our analyses, the hypertrophic phenotype of Coq10a-deleted heart seems to be different from pathological hypertrophy which occurs as a consequent of deleterious genetic mutations or in response to hypertension and ischemic injury (32, 33) . Pathological hypertrophy is often accompanied by progressive contractile dysfunction and eventually heart failure. The decrease of mitochondrial gene expression followed by reduced mitochondrial respiration often develop in pathological hypertrophy (33) . In contrast, physiological hypertrophy is a beneficial phenotype, which develop during postnatal development, pregnancy and exercise (32) . Unlike pathological hypertrophy, it increases or preserves cardiac functions with enhanced mitochondrial biogenesis (33) . Thus, our reported preserved cardiac contractile and mitochondrial functions in the Coq10a mutant mice suggest that the observed hypertrophic phenotype is more likely an enhanced physiological hypertrophy during the postnatal growth.
The mitochondrial phenotypes of Coq10a knockout mice generated in this study are different from those of coq10 yeast mutants. In yeast, the CoQ biosynthetic protein complex assembles at ER-mitochondria contact sites (1, 2), and yeast Coq10p protein is hypothesized to be a carrier of CoQ to its proper location in the inner mitochondrial membrane for functioning in the electron transport chain (4). Accordingly, yeast lacking COQ10 gene present defects in mitochondria respiration (4, 5) . In contrast, the mitochondria of Coq10a knockout heart showed normal respiration activity when normalized by the total mitochondrial protein level. Given that Coq10a mutant mice have more mitochondrial proteins but normal cardiomyocyte numbers per heart, we predict that mice lacking Coq10a would have enhanced mitochondria respiration activity per cardiomyocyte.
Additionally, despite yeast coq10 mutant shows normal levels of CoQ, Coq10a mutant mice have 2-fold increases of CoQ levels. RNA-seq analyses of P14 hearts indicates no compensatory up-regulation of Coq10b and genes involved in CoQ synthesis ( Figure S4 ), suggesting that the increase of CoQ levels might be independent of enhanced CoQ synthesis. One possible explanation for the increase of CoQ levels is that mouse Coq10a protein may work as a carrier of CoQ as what was suggested for yeast Coq10p (4), and CoQ is accumulated in the mitochondria of Coq10a mutant mice because a significant proportion of CoQ is not transported and used properly. It is still an enigma why Coq10a mutant mouse has a normal respiration rate in mitochondria unlike yeast coq10 mutant. The more ubiquitously expressed Coq10 member Coq10b (Figure S1 ) may play a redundant function with Coq10a to fulfill the role of yeast COQ10 in mammalian mitochondria. Further investigation of the physiological function of Coq10b in vivo will help test this possibility.
The molecular mechanism by which deletion of the mitochondrial protein Coq10a affects transcription of genes such as Pgc1α is still unknown. However, there are some evidences showing supplementation of CoQ 10 increases Pgc1α expression and activates PPAR pathway in mouse liver (34, 35) . In addition, coenzyme Q10 has recently been reported to be a novel potent ligand for PPARα/γ (36) . Since our mutant mice have a 2.1-fold of CoQ 10 , there is a possibility that the accumulation of CoQ triggers mitochondrial biogenesis via direct activation of PPARα/γ in our mutant mice. Nevertheless, understanding of how Coq10a regulates cardiomyocyte mitochondrial gene expression could yield new insights into the molecular control of coenzyme Q post-synthesis transport and postnatal heart hypertrophic growth.
Methods
Animals
Mice procedures were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Francisco. CD-1 (Charles River) and against Thra-GFP were described in our previous paper (19) .
Western blotting
Proteins were lysed in 1% SDS (reconstituted in PBS) supplemented proteinase inhibitor (Fisher, PI88666) from frozen P14 mouse heart ventricles. Protein concentration was measured using the BCA Protein Assay Kit (Pierce). 100mg protein lysate was first loaded to a NuPAGE 4-12%
Bis-Tris Gel (Invitrogen) for separation, and then transferred to a PVDF membrane (BIO-RAD).
Protein loading was assessed using Ponceau S staining. The blot is visualized using ECL Western
Blotting substrate (Pierce). The following primary antibodies were used: rabbit anti-Coq10a (Proteintech, 17812-1-AP, 1:1000), mouse anti-Troponin T (Thermo Fisher Scientific, MS295P1, 1:1000), mouse anti-Tom20 (Santa Cruz Biotechnology, sc-17764, 1:1000).
Gene expression analysis on neonatal CMs
For CM isolation, mice were anesthetized on ice, and then the freshly isolated heart was cannulated onto a needle and perfused with 2 mg/mL collagenase II (Worthington) until the heart loses integrity. The isolated CMs were plated on 96 well plate coated by Laminin in 5% FBS in DMEM supplemented with 1μM Ara-C and 100 μg/ml primocin. At 24 hours after the culture, the media was replaced to 0.05% BSA in DMEM supplemented with 100 μg/ml primocin, and 30nM or 300nM T3 were added. At 72 hours after culture, total RNA was isolated using TRIzol, and then cDNA was synthesized using iScript™ cDNA Synthesis Kit. qPCR was performed using the SYBR Select Master Mix (Applied Biosystems, 4472908) and the 7900HT Fast Real-Time PCR system (Applied Biosystems). Relative mRNA levels of Coq10a, Myh6 and Actb1 were measured using the 
Generation of Coq10a knockout mice
The sequence of sgRNA targeting Coq10a is TTACTCGGAGCGTAGGATCA. CD-1 (Charles River) was used to generate knockout mice. Purified sgRNA and Cas9 protein were injected into mouse-fertilized oocytes by CVRI Mouse Core Facility. Histology 3.7% paraformaldehyde (PFA) fixed hearts were embedded in paraffin, and then sectioned 5 μm thickness. For fibrosis staining, sections were soaked in Sirius Red for 25 min at room temperature. For eosin and hematoxylin staining, sections were stained with Eosin for 3 min and hematoxylin for 5 min at room temperature. Sections were imaged using Axio Scan.Z1 and fibrotic area was quantified using ImageJ.
Cardiomyocyte isolation
Mice were injected with 6.67 mg/kg bodyweight of heparin (1000 IU/mL) intraperitoneally 30 minutes before anesthetizing the mice with 20% ethyl-carbamate. The hearts were rapidly excised and the aorta was cannulated onto a Langendorff apparatus and perfused with 2 mg/mL collagenase II (Worthington). Digestion was stopped after the hearts lost partial integrity. Hearts were then unmounted from the Langendorff apparatus, ventricles isolated, and gently triturated with forceps to further release cardiomyocytes. Isolated cardiomyocytes were then fixed in 2% PFA for 15 minutes at room temperature, spotted onto glass slides, and stained with DAPI to visualize nuclei.
Cardiomyocyte size and nucleation were analyzed using ImageJ. At least 200 cells were used for the quantifications.
Immunohistochemical staining on mouse heart
Methods for sectioning and immunostaining were described in our previous paper ().
Briefly, freshly dissected heart was embedded in O.C.T. Compound and flash frozen on metal box in liquid nitrogen. Embedded samples were then sectioned with a Leica CM3050S to 5 μm thickness.
PFA-fixed sections were permeabilized in 0.2% Triton X-100 in PBS, blocked in 5% normal donkey serum (NDS) in PBST, and incubated with primary antibodies. The following primary antibodies were used: rat anti-Ki67 eFluor 570 (eBiosciences, 41-5698-80, 1:200), rabbit anti-PCM1 antibody (Sigma, HPA023370, 1:2000) and mouse anti-Troponin T (Thermo Fisher Scientific, MS295P1, 1:200) in PBST overnight at 4°C. After washing with PBST, samples were incubated in secondary antibodies with fluorescence (1:500) for 2 hours at room temperature. Cell membrane was labeled with wheat germ agglutinin (1:200) and nuclei were stained with DAPI. TUNEL staining was followed the instruction accordingly.
Quantification of total cardiomyocyte number
Hearts were fixed in 3.7% formaldehyde for 1 hour. After removal of the atria, the ventricle was then cut into four pieces and digested in PBS containing 4 mg/ml collagenase II (Worthington) with gentle shaking at 37°C until complete digestion. The digestion buffer was changed daily. All dissociated cardiomyocytes were pooled and counted using a hemocytometer.
RNA-seq analysis on Coq10a KO mice
RNA was isolated from heart samples using TRIzol Reagent (Thermo Fisher Scientific) according to a manufacturer's instruction and further pre-cleaned by Zymo RNA Clean & Concentrator 5. 1 mg of total RNA was used for library preparation with Illumina Tru-seq RNA Library Prep Kit V2. NEXTflex Unique Dual Index Barcodes (PerkinElmer) were used to minimize index hopping. Samples were normalized, pooled and sequenced on Illumina NovaSeq 6000 to obtain 50 bp paired-end reads.
Measurements of cardiac functions
Left ventricular systolic function was evaluated by two-dimensional echocardiography with Visual Sonics Vevo 3100 equipped with a 40 MHz probe. Animals were anesthetized with 0.5-1.0% isofluorane and hair was removed over the measurement area. The mice were then placed in a supine position on a heating pad. To measure ejection fraction and fractional shortening, short axis images were acquired at the level of the papillary muscle with M-mode, and the left ventricle internal dimensions (LVIDs) were determined in both diastole and systole.
Blood pressure and heart rate were measured using BP-2000 Blood Pressure Analysis System TM (Visitec Systems). The values were determined by average numbers of experimental data in three days.
Quantification of mitochondrial DNA
DNA was purified from frozen P14 heart ventricles with Proteinase K, following by phenol/chloroform extraction. qPCR was performed using the SYBR Select Master Mix (Applied Biosystems, 4472908) and the 7900HT Fast Real-Time PCR system (Applied Biosystems).
Mitochondrial DNA content was measured via qPCR targeting mitochondrial genes, ND2 and Cox1, and Relative mitochondrial DNA content was measured with qPCR targeting mitochondrial genes, ND2 and Cox2, and normalization against genomic gene, H19 using the following primers: mtND2 forward=5'-CCCATTCCACTTCTGATTACC-3'; mtND2 reverse= 5'-ATGATAGTAGAGTTGAGTAGCG-3'; mtCox1 forward =5'-CTGAGCGGGAATAGTGGGTA-3'; mtCox1 reverse= 5'-TGGGGCTCCGATTATTAGTG-3'; H19 forward =5'-GTCCACGAGACCAATGACTG-3' ; H19 reverse =5'-GTACCCACCTGTCGTCC-3'.
Separation of mitochondrial and cytosol fractions
Mitochondria Isolation Kit for Tissue (Abcam, ab110168) was used for the separation of mitochondrial and cytosol fractions. Freshly isolated whole heart was removed atria, washed with pre-chilled washing buffer, and minced in pre-chilled isolation buffer. After spinning down at 1,000g, supernatant was transferred to new tube, and then was centrifuged at 12,000g for the separation.
Supernatant containing cytosol protein was mixed with 1% SDS solution supplemented with proteinase inhibitor (PI) cocktail (Roche, 5892970001), and then was used for western blotting. The sedimented mitochondria were washed in isolation buffer supplemented with PI cocktail (Abcam, ab201111), and was used for mitochondrial respiration analysis. For western blotting, the mitochondria were dissolved in 1% SDS solution supplemented with PI cocktail (Roche, 5892970001). The protein concentration was determined using BCA assay.
Measurement of mitochondrial respiration
Seahorse Bioscience XFe24 Extracellular Flux Analyzer was used for the measurement of mitochondria respiration. 5μg of mouse heart mitochondria was plated in each wells of Seahorse XF24 24-well microplate, and added 450μl of 1X MAS containing 4% BSA, 10 mM pyruvate and 5 mM malate. Isolated mitochondria were treated with 2 μM rotenone, 10 mM succinate, 5 μM antimycin A and 100 μM cN,N,N',N'-Tetramethyl-p-phenylenediamine (TMPD) with 10mM ascorbate (Asc) at the indicated time points.
Quantifications of CoQ 9 and CoQ 10
The detail method is described previously (37) . 
